ViewRay has secured an order to supply its MRIdian MR image-guided linac at the University Hospital Zurich (USZ) in Switzerland.
USZ noted that MRIdian system was selected as the “only device that met all the latest technological requirements” and “could fit into the existing premises as a replacement device.”
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
USZ department of radiation oncology chairman Matthias Guckenberger said: “MRIdian brings a level of real-time visibility and treatment adaptation that is not possible using standard radiation therapy technology.
“We look forward to expanding our offerings to include MRIdian’s advanced imaging and delivery capabilities to enhance the level of care we bring to our patients.”
The MRIdian system delivers diagnostic-quality MR visualisation of soft-tissue targets and surrounding organs.
It facilitates daily on-table treatment plan adaptation to speedily adjust for subtle anatomical changes both during treatment delivery and throughout the course of treatment.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAltogether, these capabilities enable clinicians to enhance targeting precision and deliver potentially effective radiation doses.
An important aspect of the USZ’s MRIdian MR image-guided radiation therapy programme will be MR-guided adaptive radiotherapy, particularly stereotactic radio-surgery for treating oligo-metastatic disease, head and neck, and lung cancer.
Additionally, the new MRIdian Linac will be used as part of the hospital’s Radiomics biomarker research for response prediction and assessment, in association with the Swiss Federal Institute of Technology in Zurich (ETH).
